
    
      The primary objective of this study is to provide ongoing treatment of HGT-1111 to patients
      who have completed study HGT-MLD-048 (previously study rhASA-03 - NCT00633139) until HGT-1111
      is commercially available or the study is terminated by the Sponsor, provided no safety
      concerns have emerged. The secondary objective of this study is to monitor disease
      progression and the safety profile of HGT-1111 administered to patients who have completed
      study HGT-MLD-048 (NCT00633139).
    
  